Advertisement

Topics

FDA approves Amgen and Allergan’s rastuzumab biosimilar Kanjinti

03:27 EDT 14 Jun 2019 | Pharmaceutical Business Review

The FDA has approved Kanjinti for all approved indications of the reference product Herceptin to treat HER2-overexpressing adjuvant and metastatic breast cancer and HER2-overexpressing metastatic gastric or gastroesophageal

The post FDA approves Amgen and Allergan’s rastuzumab biosimilar Kanjinti appeared first on Pharmaceutical Business review.

Original Article: FDA approves Amgen and Allergan’s rastuzumab biosimilar Kanjinti

NEXT ARTICLE

More From BioPortfolio on "FDA approves Amgen and Allergan’s rastuzumab biosimilar Kanjinti"

Advertisement
Quick Search
Advertisement
Advertisement